Petros Pharmaceuticals, Inc. (PTPI) Income Statement
PTPI 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPTPI revenue and net income
PTPI profit margins
PTPI growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | −100.0% | — | — | — |
| Gross profit | −100.0% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PTPI quarterly EPS vs estimates
Petros Pharmaceuticals beat the analyst EPS estimate in 2 of the last 7 quarters.
PTPI income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $5.1M | $5.8M | $6.0M | $7.8M | $9.6M | $15.6M | $14.1M |
| Cost of revenue | $0 | $1.2M | $1.6M | $2.3M | $1.6M | $4.0M | $12.7M | $10.5M |
| Gross profit | $0 | $3.9M | $4.2M | $3.7M | $6.2M | $5.5M | $2.9M | $3.6M |
| Research & development | — | $2.6M | $2.4M | $1.7M | $1.8M | $459,636 | $0 | — |
| Sales, general & admin | $4.6M | $8.7M | $9.3M | $12.2M | $15.6M | $15.7M | $19.7M | $11.3M |
| Total operating expenses | $4.6M | $21.6M | $17.8M | $23.6M | $24.3M | $22.8M | $25.0M | $11.2M |
| Operating income | −$4.6M | −$17.7M | −$13.6M | −$19.9M | −$18.0M | −$17.3M | −$19.3M | −$7.7M |
| Interest income | $256,933 | $371,769 | $301,916 | $14,194 | $0 | — | — | — |
| Interest expense | — | $560,909 | $536,138 | $596,018 | $368,660 | $3.1M | $13.8M | $0 |
| Income before taxes | −$4.5M | −$14.3M | −$8.2M | −$20.0M | −$9.0M | −$22.0M | −$33.2M | −$32.5M |
| Income taxes | −$6.41B | $26.78B | $5.65B | $7.0M | $368,660 | −$1.4M | −$645,866 | −$13,365 |
| Net income | $1.9M | −$14.3M | −$8.2M | −$20.0M | −$9.0M | −$20.6M | −$32.5M | −$32.5M |
| EBITDA | −$4.5M | −$10.8M | −$4.2M | −$13.7M | −$1.7M | −$12.3M | −$14.0M | $373,576 |
| EPS (diluted) | $0.05 | −$65.82 | −$103.20 | −$2.80 | −$0.91 | −$8.11 | −$17.80 | −$6.34 |
| Gross margin | — | 76.3% | 72.0% | 61.8% | 79.5% | 57.7% | 18.4% | 25.4% |
| Operating margin | — | −345.8% | −233.9% | −332.4% | −231.1% | −180.8% | −124.0% | −54.4% |
| Net margin | — | −280.1% | −140.2% | −334.4% | −115.0% | −215.3% | −208.7% | −231.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $725,403 | $1.6M | $1.4M | $1.4M | $0 | $1.7M |
| Cost of revenue | — | — | — | — | — | — | $264,754 | $287,005 | $329,110 | $1.0M | $158,147 | $408,475 |
| Gross profit | — | — | — | — | — | — | $460,649 | $1.3M | $1.1M | $339,136 | −$522,397 | $1.3M |
| Research & development | — | — | — | — | — | — | $101,945 | $588,355 | $368,798 | $1.6M | $834,334 | $389,093 |
| Sales, general & admin | $988,501 | $1.0M | $391,486 | $990,737 | $1.8M | $1.5M | $1.4M | $2.3M | $2.3M | $2.7M | $2.9M | $2.0M |
| Total operating expenses | $988,501 | $1.0M | $391,486 | $990,737 | $1.8M | $1.5M | $9.6M | $3.6M | $3.4M | $4.3M | $4.7M | $6.1M |
| Operating income | −$988,501 | −$1.0M | −$391,486 | −$990,737 | −$1.8M | −$1.5M | −$9.1M | −$2.3M | −$2.3M | −$3.9M | −$5.0M | −$4.8M |
| Interest income | $31,976 | $40,143 | $53,280 | $67,014 | $88,849 | $47,790 | $24,741 | $75,817 | $119,391 | $151,819 | $227,589 | $168,481 |
| Interest expense | — | — | — | — | — | — | $167,459 | $158,730 | $114,512 | $120,209 | $125,821 | $131,351 |
| Income before taxes | −$955,625 | −$987,036 | −$336,506 | −$922,723 | −$2.0M | −$1.2M | −$9.3M | −$2.2M | −$662,026 | −$2.2M | $318,150 | −$4.5M |
| Income taxes | — | −$6.41B | — | — | — | $1.1M | $12.47B | $3.03B | $2.07B | $125,821 | — | $866,381 |
| Net income | −$955,625 | −$987,036 | −$336,506 | −$922,723 | $5.4M | −$2.3M | −$9.3M | −$2.2M | −$662,026 | −$2.2M | $318,150 | −$4.5M |
| EBITDA | −$988,501 | −$987,036 | −$391,486 | −$214,918 | −$2.0M | −$1.2M | −$8.4M | −$1.3M | $207,153 | −$1.3M | — | −$3.6M |
| EPS (diluted) | — | — | — | −$0.03 | −$1.58 | −$8.46 | −$1.07 | −$13.25 | −$9.25 | −$42.25 | −$54.25 | −$2.31 |
| Gross margin | — | — | — | — | — | — | 63.5% | 81.8% | 76.8% | 24.4% | — | 75.6% |
| Operating margin | — | — | — | — | — | — | −1,258.7% | −148.4% | −160.5% | −282.9% | — | −287.0% |
| Net margin | — | — | — | — | — | — | −1,278.4% | −140.9% | −46.6% | −155.7% | — | −271.7% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PTPI's financial statements (latest annual report filed April 15, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PTPI financial results
Petros Pharmaceuticals reported no revenue in fiscal year 2025 (ended December 31, 2025). It had net income of $1.9 million. Diluted earnings per share came to $0.05.
See the PTPI stock overview for the latest quote and news, or the PTPI chart for price history and technical indicators.
PTPI income statement FAQ
Does Petros Pharmaceuticals have revenue?
Petros Pharmaceuticals reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is Petros Pharmaceuticals profitable?
Yes. Petros Pharmaceuticals reported net income of $1.9 million in fiscal 2025.
What are Petros Pharmaceuticals's earnings per share?
Petros Pharmaceuticals earned $0.05 per diluted share in fiscal 2025, compared with $-65.82 a year earlier.
When does Petros Pharmaceuticals's fiscal year end?
Petros Pharmaceuticals's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 15, 2026.